Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J 
Welcome,         Profile    Billing    Logout  

56 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J
2014-002579-27: Pilot study on the efficacy of golimumab in normalizing the symptoms and lesions of the colon-rectum in patients with ulcerative colitis who only respond to therapy with cortisone

Ongoing
4
100
Europe
SIMPONI, NA, Solution for injection in pre-filled pen, SIMPONI
Istituto Clinico Humanitas, MSD Italia S.r.l.
active steroid-dependent ulcerative colitis, Chronic inflammation of the colon with symptoms and intestinal lesions that need continuous therapy with steroids., Diseases [C] - Digestive System Diseases [C06]
 
 
2015-002284-42: The rationale for this study is to gain insight in the extent and impact of immunogenicity of TNF inhibitors in the European daily clinical practice. Furthermore, an European wide database will give insight in factors influencing immunogenicity and treatment outcome in terms of disease activit

Ongoing
4
1650
Europe
etanercept, adalimumab, certolizumab pegol, golimumab, infliximab, Injection, Infusion, Enbrel, Humira, Cimzia, Simponi, Remicade
READE, PFIZER
rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and psoriasis., rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and psoriasis., Not possible to specify
 
 
2012-004482-40: Evaluation of a protocol for the reduction of doses in patients with rheumatoid arthritis (RA) in clinical remission in treatment with biological therapies Evaluación de un protocolo para la disminución de dosis en pacientes con Artritis Reumatoide (AR) en remisión clínica en tratamiento con terapias biológicas

Ongoing
4
28
Europe
Infliximab, Adalimumab, Etanercept, Certolizumab Pegol, Golimumab, Abatacept, Tocilizumab, HUMIRA, ENBREL, CIMZIA, SIMPONI, ORENCIA, RoActemra, HUMIRA, ENBREL, CIMZIA, SIMPONI, ORENCIA, RoActemra
FRANCISCO J. BLANCO GARCÍA, FRANCISCO J. BLANCO GARCIA
Evaluation of the clinical utility of a standardized protocol of strategies for the reduction of doses in patients with rheumatoid arthritis in clinical remission at treatment with biologic therapies Evaluación de la utilidad clínica de un protocolo estandarizado de estrategias para la disminución de dosis en pacientes con Artritis Reumatoide en remisión clínica a tratamiento con terapias biológicas
 
 
2016-003129-40: Remission after suspension of TNF alpha therapies in RA Remissione dopo terapia con farmaci Anti TNF in pazienti affetti da Artrite Reumatoide

Ongoing
4
60
Europe
HUMIRA (ADALIMUMAB), CIMZIA (Certolizumab Pegol), ENBREL (Etanercept), REMICADE (INFLIXIMAB), SIMPONI (GOLIMUMAB), [NA], [-], Solution for injection, Powder and solvent for solution for injection, Powder for solution for injection, HUMIRA - 40 MG SOLUZIONE INIETTABILE USO SOTTOCUTANEO 2 SIRINGHE PRERIEMPITE 0.8 ML + 2 TAMPONI IMBEVUTI DI ALCOL IN 1 BLISTER, CIMZIA - 200MG-SOLUZIONE INIETTABILE-USO SOTTOCUTANEO-SIRINGA PRERIEMPITA(VETRO) 1ML 6(3X2) SIRINGHE PRERIEMPITE+6(3X2) SALVIETTINE IMBEVUTE DI ALCOOL, ENBREL - 50 MG POLV SOLUZ INIET SOTTOC. POLV. FLAC VETRO SOLV. SIRI. VET. SOLV 1 ML (50 MG/ML) 12 FLAC+12 SIRI. PRE+12 AGHI+12 ADAT PER FLAC+24 TAMP. PRE INIEZ, REMICADE - 100 MG POLVERE PER CONCENTRATO PER INFUSIONE ENDOVENOSA 1 FLACONE VETRO 20 ML USO EV, SIMPONI - 50 MG-SOLUZIONE PER INIEZIONE IN PENNA PRERIEMPITA-USO SOTTOCUTANEO-PENNA PRERIEMPITA(VETRO) -0.5 ML 3 (3X1) PENNE PRERIEMPITE
AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA, AIFA - Italian Medicines Agency
RHEUMATOID ARTHRITIS (RA) PATIENTS PAZIENTI AFFETTI DA ARTRITE REUMATOIDE (AR), RHEUMATOID ARTHRITIS (RA) PATIENTS PAZIENTI AFFETTI DA ARTRITE REUMATOIDE (AR), Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2017-001374-42: Measuring levels of golimumab to improve the understanding of differences in its effectiveness amongst patients with ulcerative colitis

Not yet recruiting
4
112
Europe
Golimumab, Solution for injection in pre-filled pen, Simponi
Guy's and St Thomas' NHS Foundation Trust, Merck Sharp & Dohme
Ulcerative Colitis (UC), Ulcerative Colitis (UC), Diseases [C] - Digestive System Diseases [C06]
 
 
2017-001970-41: Dose reduction and withdrawal of biological therapy in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: Protocol for a 18 months multi-centre trial

Ongoing
4
180
Europe
Abatacept, Adalimumab, Certolizumab pegol, Etanercept, Golimumab, Infliximab, Tocilizumab, L04AA24, L04AB04, L04AB05, L04AB01, L04AB06, L04AB02, L04AC07, Concentrate for solution for injection, Concentrate and solvent for solution for infusion, Concentrate and solvent for solution for injection, Concentrate and solvent for suspension for injection, Orencia, Humira, Cimzia, Enbrel, Benepali, Simponi, Remsima, Remicade, RoActemra, Inflectra, Imraldi, Amgevita
MD, PhD Salome Kristensen, The Danish Regions (Regionernes Medicinpulje), The Department of Rheumatology at Aalborg University Hospital, Health Science Research Fund of the Region of Northern Jutland
Rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis, Rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis (arthritis of the spine), Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2018-003432-72: Dose reduction and withdrawal of TNF inhibitors in patients with Psoriatic Arthritis and Axial Spondyloarthritis Afbouwen en stoppen van TNF remmers bij patiënten met Artritis Psoriatica en Axiale Spondylartritis.

Ongoing
4
234
Europe
Adalimumab, Certolizumab, Etanercept, Golimumab, Infliximab, Solution for injection/infusion, Tumor Necrosis Factor alpha (TNF-a) Inhibitors: Adalimumab, Certolizumab, Etanercept, Golimumab, Infliximab
Sint Maartenskliniek, Sint Maartenskliniek
Adults diagnosed with Psoriatic Arthritis en Axial Spondyloarthritis. Volwassenen gediagnosticeerd met artritis psoriatica en axiale spondylartritis., Psoriatic arthritis and Axial Spondyloarthritis Artritis psoriatica en axiale spondylartritis, Diseases [C] - Immune System Diseases [C20]
 
 
2018-002925-47: prediction of response to therapy in inflammatory bowel disease Predicción de respuesta al tratamiento en la enfermedad inflamatoria intestinal

Not yet recruiting
4
180
Europe
Injection, Infusion, Adalimumab, Infliximab, Golimumab, Ustekinumab, Vedolizumab
Fundación de Investigación Biomédica del Hospital Universitario de La Princesa, Instituto de Salud Carlos III
Inflammatory bowel disease Enfermedad inflamatoria intestinal, Corhn´s disease and ulcerative colitis Enfermedad de Crohn y colitis ulcerosa, Diseases [C] - Digestive System Diseases [C06]
 
 
2016-000152-96: Intensive Treatment to Reach the target with Golimumab in ulcErative coliTis – In-TARGET Traitement intensif par golimumab pour atteindre la cible thérapeutique dans la rectocolite hémorragique (RCH) - In-TARGET

Not yet recruiting
4
200
Europe
Solution for injection, SIMPONI 50 mg, SIMPONI 100 mg
GETAID, Pharmaceutical company
Moderate to severe ulcerative colitis Rectocolite hémorragique modérée à sévère, Moderate to severe ulcerative colitis who failed corticosteroids and immunosuppressive therapy, or are intolerant to immunosuppressors. Rectocolite hémorragique (RCH) modérée à grave pour laquelle un traitement avec des anticorps dirigés contre le facteur de nécrose tumorale (TNF) est jugé nécessaire., Diseases [C] - Digestive System Diseases [C06]
 
 
2019-003987-37: Comparison of Two Different Golimumab Dosing Regimens for Ulcerative Colitis Primerjava dveh različnih shem odmerjanja golimumaba pri ulceroznem kolitisu

Not yet recruiting
4
30
Europe
Simponi, CNTO-148, Solution for injection in pre-filled pen, Simponi
University Medical Centre Ljubljana, Department of gastroenterology, University Medical Centre Ljubljana, Department of gastroenterology
Ulcerative colitis Ulcerozni kolitis, Inflammatory bowel disease - ulcerative colitis Kronična vnetna črevesna bolezen - ulcerozni kolitis., Diseases [C] - Digestive System Diseases [C06]
 
 
2020-004391-18: IMPACT OF ANTI-TNF, VEDOLIZUMAB AND TOFACITINIB ON AORTIC STIFFNESS, CAROTID INTIMA-MEDIA THICKNESS AND CARDIOVASCULAR RISK OF PATIENTS WITH ULCERATIVE COLITIS Impact des anti-TNF, du vedolizumab et du tofacitinib sur la rigidité aortique, l'épaisseur de l'intima-média carotidienne et le risque cardiovasculaire des patients atteints de rectocolite hémorragique

Not yet recruiting
4
100
Europe
Inflectra 100 mg, AMGEVITA, Simponi, Entyvio 300 mg, XELJANZ, Powder and solvent for concentrate for solution for infusion, Solution and suspension for suspension for injection in pre-filled syringe, Solution for injection in pre-filled pen, Tablet, Inflectra 100 mg, AMGEVITA, Simponi, Entyvio 300 mg, XELJANZ
CHU Amiens-Picardie, Pfizer
ulcerative colitis rectocolite hémorragique, ulcerative colitis rectocolite hémorragique, Diseases [C] - Digestive System Diseases [C06]
 
 
2021-002211-65: EFFECT OF TOFACITINIB ON COAGULATION EFECTO DE TOFACITINIB SOBRE LA COAGULACIÓN

Ongoing
4
60
Europe
Injection, Infusion, Pastille, Adalimumab, Infliximab, Golimumab, Tofacitinib
Fundación Española de Gastroenterología, pfizer
ulcerative colitis colitis ulcerosa, ulcerative colitis colitis ulcerosa, Body processes [G] - Biological Phenomena [G16]
 
 
TARGET, NCT02425865: Intensive Treatment to Reach the Target With Golimumab in ulcErative coliTis - In-

Completed
4
202
Europe
GOLIMUMAB
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
ULCERATIVE COLITIS
10/21
01/23
NCT04156984: Comparison of Two Different Golimumab Dosing Regimens for Ulcerative Colitis

Not yet recruiting
4
30
Europe
Golimumab Prefilled Syringe
David Drobne
Ulcerative Colitis
11/22
11/22
NCT05313620: Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events

Recruiting
4
30
Europe
Tofacitinib, Infliximab Adalimumab y Golimumab
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Ulcerative Colitis, Thromboembolism
10/24
10/24
BioIBD, NCT03885713: Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease

Recruiting
4
180
Europe
Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab or tofacitinib
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
12/24
12/24
BIOTAPE, NCT05115903: Biologic Tapering Study of TNF Inhibitors in Axial Spondyloarthritis

Active, not recruiting
4
15
Canada
Tapered doses of TNFi, etanercept 50 mg every 10 days (75% of baseline dose), 14 days (50%), 30 days (25%), adalimumab 40 mg every 3 weeks (75%), 4 weeks (50%), 16 weeks (25%), certolizumab pegol 200 mg 3 weeks (75%), 4 weeks (50%), 16 weeks (25%), golimumab 50 mg every 6 weeks (75%), 8 weeks (50%), 16 weeks (25%), infliximab 5 mg/kg every 8 weeks (75%), 12 weeks (50%), 16 weeks (25%), Standard dose of TNFi, etanercept 50 mg every 7 days, adalimumab 40 mg every 2 weeks, certolizumab pegol 200 mg every 2 weeks, golimumab 50 mg every 4 weeks, infliximab 5 mg/kg every 6 weeks
University Health Network, Toronto
Axial Spondyloarthritis
07/24
08/24
COVER, NCT05080218: COVID-19 VaccinE Response in Rheumatology Patients

Recruiting
4
1000
US
Upadacitinib, Rinvoq, Abatacept, Orencia SQ, Secukinumab, Cosentyx, Tofacitinib, Xeljanz, TNF Inhibitor, Etanercept, Certolizumab, Golimumab SQ, Adalimumab, Canakinumab Injection, Ilaris, Baricitinib, Olumiant, Ixekizumab, Taltz
Jeffrey Curtis, University of Alabama at Birmingham, University of Nebraska, University of Pennsylvania, AbbVie, Bristol-Myers Squibb, Novartis, Eli Lilly and Company, Pfizer, Illumination Health
Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis
02/24
09/24
ChiCTR2000033582: Study of Efficacy and safety with golimumab in the treatment of children’s rheumatic diseases

Not yet recruiting
4
300
 
golimumab IH ;Oral traditional medicine
Guangzhou Women and Children's Medical Center; Guangzhou Women and Children's Medical Center, Guangzhou Women and Children’s Medical Center,Internal Medicine Fund Project
Rheumatic diseases in children
 
 
2011-003678-97: Exploration of TNF-alpha Blockade with golimumab in the Induction of Clinical Remission in Patients with Early Peripheral Spondyloarthritis (SpA) according to ASAS-criteria Exploratie van TNF alfa blokkade met golimumab met als doel het induceren van klinische remissie bij patiënten met perifere spondyloarthropathie met vroegtijdige aantasting die voldoen aan de huidige ASAS criteria (CRESPA).

Ongoing
3
60
Europe
golimumab, LEDERTREXATE, Solution for injection in pre-filled syringe, Tablet, Simponi, LEDERTREXATE
Ghent University Hospital, Gheny University Hospital, Janssen Biologics BV
Early stage peripheral Spondyloarthritis (SpA) Vroegtijdige Perifere sponyloarthropathie, Early stage Peripheral Spondyloarthritis Perifere spondyloarthropathie met vroegtijdige aantasting, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
NCT01777399 / 2009-015019-42: A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS)

Active, not recruiting
3
173
US, Canada, Europe, RoW
CNTO 148 (Golimumab), CNTO 148 (golimumab) or placebo
Janssen Research & Development, LLC, Schering-Plough (Ireland) Company
Juvenile Idiopathic Arthritis
09/13
04/16
2012-005214-19: A randomized, double-blind, placebo-controlled trial of golimumab+methotrexate versus methotrexate alone in methotrexate-naïve patients with psoriatic arthritis Een gerandomiseerd, dubbel blind, placebo gecontroleerde studie van golimumab+methotrexaat ten opzichte van methotrexaat alleen in methotrexaat-naieve patienten met artritis psoriatica

Ongoing
3
60
Europe
Golimumab, Simponi, Simponi
Academic Medical Center, Department of Rheumatology, Academic Medical Center, department of Rheumatology
active psoriatic arthritis actieve artritis psoriatica
 
 
2017-001728-23: Efficacy of golimumab in early axial spondyloarthritis (axSpA) in relation to gut inflammation, an early remission induction study (GO GUT).

Ongoing
3
147
Europe
Solution for injection in pre-filled pen, Simponi
Ghent University, Merck Sharp & Dohme, Vlaams Instituut voor Biotechnologie
early axial spondyloarthritis (axSpA) in relation to gut inflammation, early axial spondyloarthritis (axSpA) in relation to gut inflammation, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
GO-VIVA, NCT02277444: A Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Intravenous Golimumab in Pediatric Participants With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy

Active, not recruiting
3
130
Canada, US, RoW
Golimumab, Simponi Aria, Methotrexate
Janssen Research & Development, LLC
Arthritis, Juvenile
07/18
02/29
2019-004961-42: Strategy study in patients with peripheral spondyloarthritis, in which it is investigated whether induction of remission can be achieved more quickly with early treatment with a TNF-alpha blocker, compared to standard treatment, and in which also factors (blood, joint biopsy) that predict these outcome are investigated. Strategie-studie bij patiënten met perifere spondyloartritis, waarbij nagegaan wordt of inductie van remissie sneller bereikt kan worden met vroegtijdige behandeling met een TNF-alfa blokker, in vergelijking met de standaardbehandeling, en waarbij tevens onderzoek gebeurt naar factoren (bloed, gewrichtsbiopsie) die deze uitkomst zouden kunnen voorspellen.

Not yet recruiting
3
112
Europe
Capsule, Solution for injection in pre-filled injector, Solution for injection in pre-filled syringe, Ledertrexate, Simponi
Ghent University Hospital, VIB vzw, MSD Belgium
peripheral spondyloarthritis Perifere spondyloartritis, rheumatic inflammatory disease against the joints and tendons outside the vertebral column reumatische ontstekingsziekte tegenover de gewrichten en pezen buiten de wervelzuil, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2020-001899-14: An unblinded clinical Trial with random assignment to Treatment Groups in adult patients with psoriatic arthrits to evaluate how far immunosuppressive medication can be tapered without recurrence of symptoms

Not yet recruiting
3
270
Europe
Prednisolone p.o., Sulfasalazine, Leflunomide, Methotrexate p.o., Methotrexate s.c., Etanercept, Adalimumab, Infliximab, Abatacept s.c., Abatacept i.v., Tablet, Coated tablet, , Solution for injection, Powder for concentrate for solution for infusion, Solution for injection in pre-filled pen, Solution for injection in pre-filled syringe, Solution for injection in dose-dispenser cartridge, Prolonged-release tablet, Xeljanz 5/10mg Filmtabletten, Otezla Filmtabletten, Simponi 50mg Injektionslösung Vorgefüllter Injektor/Fertigspritze, Cimzia 200mg Injektionslösung in einem Fertigpen, Orencia Injektionslösung in einer Fertigspritze, Orencia 250mg Pulver, Cosentyx 150mg Injektionslösung in einer Fertigspritze, Taltz, Cimzia 200mg Injektionslösung in einer Fertigspritze, Cimzia 200mg Injektionslösung in einer Patrone für ein Dosiergerät, Orencia 125mg Injektionslösung im Fertigpen, Cosentyx 150mg Injektionslösung in einem Fertigpen, Stelara 45mg/90mg Injektionslösung, Xeljanz 11mg Retardtablette, Rinvoq 15 mg Retardtablette, Tremfya 100mg Injektionslösung, Skyrizi 75/150mg Injektionslösung
Universitätsklinikum Erlangen, Universitätsklinikum Erlangen
Psoriatic arthritis Psoriasisarthritis, Psoriatic arthritis Gelenkbeteiligung bei Schuppenflechte, Diseases [C] - Immune System Diseases [C20]
 
 
2022-001825-63: A Clinical Study to Investigate the Comparative Efficacy, Safety, and Immunogenicity Between Subcutaneous AVT05 and EU-approved Simponi® in Combination with Methotrexate in Subjects with Moderate to Severe Rheumatoid Arthritis

Not yet recruiting
3
472
Europe, RoW
golimumab, Simponi, AVT05, Solution for injection in pre-filled syringe, Simponi
Alvotech Swiss AG, Alvotech Swiss AG
Rheumatoid Arthritis reumatoidiniu artritu, Rheumatoid Arthritis reumatoidiniu artritu, Diseases [C] - Immune System Diseases [C20]
 
 
SYBRA, NCT05379322: The Use of Synovial Biopsies in Predicting Response to Biologic Therapy in Rheumatoid Arthritis Patients

Withdrawn
3
145
RoW
Anti-TNF, Adalimumab, etanercept, certolizumab, or golimumab, JAK inhibitor, Tofacitinib, baricitinib, or upadacitinib
Abu Dhabi Stem Cells Center
Rheumatoid Arthritis
10/23
04/24
NCT05046431: Comparative Study of BAT2506 With Simponi® in Participants With Active Psoriatic Arthritis

Completed
3
704
RoW
BAT2506, EU Simponi
Bio-Thera Solutions
Psoriatic Arthritis
10/23
10/23
GO-GUT, NCT03270501: Efficacy of Golimumab in Early Axial Spondyloarthritis in Relation to Gut Inflammation

Completed
3
64
Europe
Golimumab, ileocoloscopy
University Ghent, Merck Sharp & Dohme LLC, the Flanders Institute for Biotechnology
Axial Spondyloarthritis
12/23
12/23
PURSUIT 2, NCT03596645 / 2017-004496-31: A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis

Active, not recruiting
3
84
Europe, US, RoW
Golimumab, Infliximab
Janssen Research & Development, LLC
Colitis, Ulcerative
06/24
08/27
NCT04610476: Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis

Recruiting
3
270
Europe
Prednisolone, Prednisolone generic drugs, Sulfasalazine, Azulfidine, Leflunomide, Arava, Methotrexate, Lantarel, Metex, Tofacitinib, Xeljanz, Apremilast, Otezla, Etanercept, Enbrel, Erelzi, Benepali, Adalimumab, Humira, Amgevita, Imraldi, Hyrimoz, Infliximab, Remicade, Zessly, Inflectra, Certolizumab pegol, Cimzia, Golimumab, Simponi, Abatacept, Orencia, Secukinumab, Cosentyx, Ixekizumab, Taltz, Ustekinumab, Stelara
University of Erlangen-Nürnberg Medical School
Psoriatic Arthritis, Withdrawal, Reduction
10/24
10/25
NCT03414502: Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response

Recruiting
3
400
US
Methotrexate, Methotrexate (MTX), Abatacept, Orencia, Adalimumab, Humira, Azathioprine, Imuran, Baricitinib, Olimuant, Certolizumab, Cimzia, Etanercept, Enbrel, Golimumab, Simponi, Hydroxychloroquine, Plaquenil, Infliximab, Remicade, Leflunomide, Arava, Minocycline, Minocin, Rituximab, Rituxin, Sarilumab, Kevzara, Sulfasalazine, Azulfidine, Tofacitinib, Xeljanz
University of Nebraska
Rheumatoid Arthritis
03/26
03/28
NCT05631457: Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients (EVOLUTION)

Not yet recruiting
3
300
US
Guselkumab Prefilled Syringe [Tremfya], Tremfya, Golimumab, Simponi
University of Pennsylvania, Janssen Scientific Affairs, LLC
Psoriatic Arthritis
05/25
05/25
EVOLUTION, NCT05669833: Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients

Recruiting
3
300
US
Guselkumab, Tremfya, Golimumab, Simponi, Placebo
University of Pennsylvania, Janssen Scientific Affairs, LLC
Psoriatic Arthritis
05/26
05/26
2021-002012-31: A Study of the Efficacy and Safety of Guselkumab and Golimumab in Participants with Active Psoriatic Arthritis Estudio para evaluar la eficacia y la seguridad de Guselkumab y Golimumab en pacientes con artritis psoriásica activa

Ongoing
2
90
Europe
guselkumab, golimumab, CNTO1959, CNTO148, Solution for injection in pre-filled syringe
Janssen-Cilag International NV, JANSSEN CILAG INTERNATIONAL NV, Janssen Research & Development
Active Psoriatic Arthritis Artritis Psoriásica Activa, Psoriatic Arthritis Artritis Psoriásica, Diseases [C] - Immune System Diseases [C20]
 
 
2018-001510-15: A Proof-of-concept Study of the Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

Not yet recruiting
2
210
Europe
Guselkumab, Golimumab, CNTO1959, CNTO148, Solution for infusion in pre-filled syringe, Solution for injection in pre-filled syringe, TREMFYA®, Simponi®
Janssen-Cilag International NV, Janssen Research & Development, LLC
Ulcerative Colitis, Inflammation of Digestive Tract, Diseases [C] - Digestive System Diseases [C06]
 
 
NCT04218565: Golimumab for the Treatment of Refractory Behcet's Uveitis

Terminated
2
1
RoW
Golimumab (GOL)
Wenjie Zheng
Behcet Syndrome, Uveitis
12/22
12/22
AFFINITY, NCT05071664 / 2021-002012-31: A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis

Active, not recruiting
2
91
Europe, US, RoW
Guselkumab, TREMFYA, CNTO1959, Golimumab, SIMPONI, CNTO148, Placebo
Janssen Research & Development, LLC, Janssen Research & Development
Arthritis, Psoriatic
05/24
08/24
DUET-CD, NCT05242471 / 2021-003314-39: A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

Recruiting
2
715
Europe, Canada, Japan, US, RoW
Guselkumab, Golimumab, JNJ-78934804, Placebo
Janssen Research & Development, LLC, Janssen Research & Development
Crohn's Disease
05/25
03/29
DUET-UC, NCT05242484 / 2021-005528-39: A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

Recruiting
2
550
Europe, Canada, Japan, US, RoW
Guselkumab, Golimumab, JNJ-78934804, Placebo
Janssen Research & Development, LLC, Janssen Research & Development
Colitis, Ulcerative
05/25
03/29
TRAMP, NCT05960578: Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, Study

Recruiting
2
34
US
Apalutamide, ARN 509, ARN-509, ARN509, Erleada, JNJ 56021927, JNJ-56021927, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Golimumab, CNTO 148, Immunoglobulin G1, Anti-(Human Tumor Necrosis Factor Alpha) (Human Monoclonal CNTO 148 Gamma-1-Chain), Disulfide with Human Monoclonal CNTO 148 Kappa-Chain, Dimer, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, PSMA PET Scan, Prostate-specific Membrane Antigen PET, PSMA PET, PSMA-Positron emission tomography
University of Washington, Janssen Scientific Affairs, LLC
Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma
03/27
12/27
NCT01900574 / 2012-004366-18: A Study to Assess the Safety and Pharmacokinetics of Subcutaneously Administered Golimumab, a Human Anti-TNFα Antibody, in Pediatric Patients With Moderate to Severe Active Ulcerative Colitis

Completed
1b
35
Europe, Canada, US, RoW
Golimumab, Simponi
Janssen Research & Development, LLC
Colitis, Ulcerative
02/15
09/22
ChiCTR1900022727: A Randomized, Double-blinded, Single-dose, 2-arm Parallel, Comparative Study to Evaluate the Pharmacokinetics and Safety of BAT2506?Injection vs Simponi in Healthy Chinese Male Subjects

Not yet recruiting
1
182
 
BAT2506 injection, 50mg, subcutaneous injection ;Simponi, 50mg, subcutaneous injection
First Hospital of Jilin University; Level of the institution：, self-finance
Psoriatic arthritis/Rheumatoid Arthritis
 
 
NCT05332730: A Study on Pharmacokinetics and Safety of BAT2506 Injection Versus Simponi®

Completed
1
375
RoW
BAT2506 injection, Simponi® (EU commercially available product), Simponi® (US commercially available product)
Bio-Thera Solutions, The First Hospital of Jilin University
Psoriatic Arthritis
06/23
07/23
NCT05632211: A Study to Investigate the PK, Safety, and Tolerability Between AVT05, US and EU Simponi® in Healthy Adult Participants

Completed
1
336
Europe, RoW
AVT05, Simponi, Golimumab
Alvotech Swiss AG, Iqvia Pty Ltd
Healthy Adult Subjects
10/23
10/23
NCT04531423: PKC as Serum Biomarkers for Depression

Not yet recruiting
N/A
100
NA
SSRI + golimumab, SSRI + placebo
Shanghai Mental Health Center
Major Depressive Disorder
09/22
09/22
BIOSTOP, NCT03011268 / 2016-001409-18: Anti-tumor Necrosis Factor in Patients With Ulcerative Colitis in Clinical Remission: to Continue or Not?

Active, not recruiting
N/A
174
Europe
Discontinuation of anti-TNF treatment, Remicade, Remsima, Inflectra, Humira, Simponi, Continuation of anti-TNF treatment
Helse Møre og Romsdal HF, Oslo University Hospital, University of Oslo
Colitis,Ulcerative
02/23
02/25
NCT03945903: Pre-Approval Access to Golimumab Subcutaneous for the Treatment of Stage 3 Type-1 Diabetes Mellitus in Children and Young Adults

No Longer Available
N/A
US
Golimumab, SIMPONI
Janssen Research & Development, LLC
Diabetes Mellitus, Type 1
 
 
NCT03729349: Golimumab for Adherence in Rheumatoid Arthritis

Completed
N/A
222
Canada
Golimumab, SIMPONI ™
Janssen Inc.
Arthritis, Rheumatoid
06/23
06/23
NCT05119452: Screening for Flare After b/tsDMARD Discontinuation in Rheumatoid Arthritis

Not yet recruiting
N/A
85
NA
Discontinuation of biological/targeted synthetic disease modifying anti-rheumatic drug (b/tsDMARD), b/tsDMARD: Adalimumab, Infliximab, Golimumab, Certolizumab pegol, Tocilizumab, Sarilumab, Etanercept, Anakinra, Filgotinib, Updacitinib, Tofacitinib, Baricitinib
Medical University of Vienna, Medical University of Graz, Medical University Innsbruck, Hospital Hietzing, Krankenhaus Bruneck
Rheumatoid Arthritis
09/24
09/24
SUPRA, NCT05305066: Stand UP to Rheumatoid Arthritis

Recruiting
N/A
75
Canada
TNFi, Etanercept, Adalimumab, Golimumab, Certolizumab, Anti-IL6, Tocilizumab, Sarilumab, JAKi, Tofacitinib, Upadacitinib, Baricitinib
Marie Hudson, MD, McGill University Health Centre/Research Institute of the McGill University Health Centre, Montreal General Hospital, Lady Davis Institute
Rheumatoid Arthritis
12/25
12/26
NCT04156425: The Role of PKC Activation in the Immune-inflammatory Mechanism of Major Depressive Depression

Not yet recruiting
N/A
180
NA
Escitalopram+golimumab, Lexapro+Simponi, Escitalopram+Calcium Tablet, Lexapro+Caltrate, Escitalopram, Lexapro
Shanghai Mental Health Center
Major Depressive Disorder
12/24
12/24
COMMIT, NCT05702879: Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success

Recruiting
N/A
240
Europe
Ozanimod, TNF Inhibitor, infliximab, adalimumab, etanercept, golimumab, and certolizumab., Steroids, Prednisolon, Vedolizumab, Ustekinumab
Insel Gruppe AG, University Hospital Bern, Bristol-Myers Squibb
Ulcerative Colitis
01/25
01/25
NeuMRA, NCT04378621: Effect of Antiinflammatory Treatment Versus Hand Training on Neuropsychiatric Comorbidity in RA-patients

Active, not recruiting
N/A
212
Europe
TNF-α inhibitor OR JAK inhibitor, TNF-a inhibitors: Etanercept (Enbrel, Benapali), Infliximab (Remicade, Inflectra, Flixabi), Adalimumab (Humira, Imraldi, AMGEVITA), Certolizumabpegol (Cimzia), Golimumab (Simponi), JAK-inhibitors: Baricitinib (Olumiant), Tofacitinib (Xeljanz), Hand training, physiotherapy of hands
Vastra Gotaland Region
Rheumatoid Arthritis, Pain, Fatigue, Cognitive Decline, Depression, Brain Diseases, Hand Rheumatism
09/25
09/25
CHOIR, NCT04725422: CHronic Nonbacterial Osteomyelitis International Registry

Recruiting
N/A
2000
US
Methotrexate, Sulfasalazine, Leflunomide, Pamidronate, Zoledronic acid, Etanercept, Adalimumab, Certolizumab, Infliximab, Golimumab, NSAID
Seattle Children's Hospital, Boston Children's Hospital, Boston, MA, USA, Hospital for Special Surgery, New York City, NY, USA, Joseph M Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack, NJ, USA, Riley Children's Hospital, Indianapolis, IN, USA, University of North Carolina, Chapel Hill, NC, USA, Royal Children's Hospital, Melbourne, Australia, Hacettepe University, Ankara, Turkey, Bambino Gesù Children's Hospital, Rome, Italy, University of British Columbia, Vancouver, BC, Canada, Meyer Children's Hospital, Florence, Italy, Mansoura University
Chronic Nonbacterial Osteomyelitis, Chronic Recurrent Multifocal Osteomyelitis
08/28
08/50

Download Options